Alan Forrest
Impact in
- Molecular Medicine top 0.05%
- Antibiotic Resistance in Bacteria
- Pharmacology top 0.05%
- Antibiotics Pharmacokinetics and Efficacy
- Pharmacogenetics and Drug Metabolism
Papers in
- Pharmacology 133
- Antibiotics Pharmacokinetics and Efficacy 132
- Pharmacogenetics and Drug Metabolism 26
-
- Antibiotic Resistance in Bacteria 37
- Co-authors
- Jerome J. Schentag (25 shared papers)Mary C. Birmingham (7 shared papers)Jian Li (44 shared papers)Roger L. Nation (37 shared papers)Sujata M. Bhavnani (38 shared papers)Brian T. Tsuji (49 shared papers)Pamela A. Moise-Broder (3 shared papers)Charles H. Ballow (13 shared papers)
- Journals
- Antimicrobial Agents and Chemotherapy (89 papers)Clinical Pharmacology & Therapeutics (16 papers)The Journal of Clinical Pharmacology (12 papers)Journal of Antimicrobial Chemotherapy (10 papers)Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (8 papers)
- Partner nations
- United StatesAustraliaUnited Kingdom
In The Last Decade
Alan Forrest
293 papers receiving 16k citations
Alan Forrest's Hit Papers
Peers
Comparison fields: 5 of 158
- Molecular Medicine 3.3k
- Pharmacology 6.5k
- Applied Microbiology and Biotechnology 727
- Infectious Diseases 2.3k
- Critical Care and Intensive Care Medicine 306
Countries citing papers authored by Alan Forrest
This map shows the geographic impact of Alan Forrest's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Forrest with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Forrest more than expected).
Fields of papers citing papers by Alan Forrest
This network shows the impact of papers produced by Alan Forrest. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Forrest. The network helps show where Alan Forrest may publish in the future.
Co-authors
The 25 scholars most cited alongside Alan Forrest, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 297 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients Hit paper breakdown → | 1993 | 985 |
| 2 | Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia Hit paper breakdown → | 2004 | 749 |
| 3 | International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP) Hit paper breakdown → | 2019 | 740 |
| 4 | Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections Hit paper breakdown → | 2004 | 651 |
| 5 | Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients Hit paper breakdown → | 2011 | 619 |
| 6 | Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice Anymore Hit paper breakdown → | 2006 | 606 |
| 7 | 1998 | 443 | |
| 8 | 2010 | 369 | |
| 9 | Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens Hit paper breakdown → | 2013 | 369 |
| 10 | 2004 | 295 | |
| 11 | 2003 | 269 | |
| 12 | 2016 | 221 | |
| 13 | 2007 | 209 | |
| 14 | 2007 | 186 | |
| 15 | Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. | 1985 | 170 |
| 16 | 2007 | 168 | |
| 17 | 2000 | 165 | |
| 18 | 2016 | 162 | |
| 19 | 2011 | 156 | |
| 20 | 2010 | 150 |
About Alan Forrest
Alan Forrest is a scholar working on Pharmacology, Molecular Medicine, Infectious Diseases, Pharmacology and Pediatrics, Perinatology and Child Health, having authored 297 papers that have together received 16.9k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (132 papers), Antibiotic Resistance in Bacteria (37 papers), HIV/AIDS drug development and treatment (26 papers), Pharmacogenetics and Drug Metabolism (26 papers), Antimicrobial Resistance in Staphylococcus (18 papers), Pharmaceutical studies and practices (18 papers), Statistical Methods in Clinical Trials (15 papers) and Plant Diversity and Evolution (11 papers). The work is most often cited by research in Molecular Medicine (3.3k citations), Pharmacology (6.5k citations), Applied Microbiology and Biotechnology (727 citations), Infectious Diseases (2.3k citations) and Critical Care and Intensive Care Medicine (306 citations). Alan Forrest has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Jerome J. Schentag, Mary C. Birmingham, Jian Li, Roger L. Nation, Sujata M. Bhavnani, Brian T. Tsuji, Pamela A. Moise-Broder, Charles H. Ballow, George Sakoulas and Jürgen B. Bulitta. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics, The Journal of Clinical Pharmacology, Journal of Antimicrobial Chemotherapy and Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.